Brought to you by 
Valeant pays €314mm in cash for AB Sanitas
May 2011
Executive Summary
Keeping in line with its goal to acquire five ex-US companies before the end of 2011, Valeant Pharmaceuticals International Inc. (neurology and dermatology therapies) has agreed to buy publicly traded Lithuanian generic drug maker AB Sanitas for €314mm ($442mm) in cash and it will assume €50mm in debt.
Deal Industry
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant pays €314mm in cash for AB Sanitas
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice